B-CAG-luc Hep 3B (v2) Cell Line

Basic Information

Strain Name
Hep 3B Gt(AAVS1)tm2(luciferase)/Bcgen
Stock Number
B-HCL-021
Common Name
B-CAG-luc Hep 3B(v2)
Disease
Hepatocellular carcinoma
Species
Human
Growth factors
Adherent
Resistence
None
Culture medium
MEM+10%FBS+1% L-Glutamine+1% NEAA+1% Sodium pyruvate+1%HEPES
Frozen
95% (MEM+10%FBS)+5% DMSO
Notice
Biocytogen provides engineering service to generate the humanized tumor cell lines from customer’s own cell lines. Our humanized tumor cell lines are for pharmacology services ONLY.

Targeting Strategy

Gene targeting strategy for B-CAG-luc Hep 3B(v2) . The luciferase cDNA sequence with CAG promoter was inserted in the AAVS1 locus exon1 of wild-type Hep 3B.

Details

Phenotypic Analysis

The luminescence signal intensity of B-CAG-luc Hep 3B (v2) cells. The luminescence intensity was detected by Bright-GloTM luciferase Assay System (Promega, Cat E2610), and B-CAG-luc Hep 3B (v2) cells have strong luminescence signal.

Tumor Growth Curve & Body Weight Changes

Subcutaneous xenograft tumor growth of B-CAG-luc Hep 3B (v2) cells. B-CAG-luc Hep 3B (v2) cells and wild-type Hep 3B cells (8×106) were subcutaneously implanted into the B-NDG mice (n=4).Tumor size and mice body weight were measured twice a week. (A) Tumor average volume ± SEM, (B) Mice body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5a X b2, where a and b were the long and short diameters of the tumor, respectively. As shown in panel A, B-CAG-luc Hep 3B (v2) were able to establish tumor in vivo and can be used for efficacy study.

In vivo Imaging Analysis

Tumor growth and in vivo imaging of B-CAG-luc Hep 3B (v2) cells. B-CAG-luc Hep 3B (v2) and wild-type Hep 3B(8×106) were injected by tail vein into B-NDG mice (n=?). Signal intensity was measured twice a week. (A) Imaging was performed on days 0, 3, 7, 10, 14, 17, 21, 24, 28, 31, 35 and 38, (B)Tumor signal intensity changes. B-CAG-luc Hep 3B (v2) cells can be used for in vivo efficacy evaluation.

Back to top